Volume | 1,570,708 |
|
|||||
News | - | ||||||
Day High | 0.6888 | Low High |
|||||
Day Low | 0.6404 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Atara Biotherapeutics Inc | ATRA | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
0.66 | 0.6404 | 0.6888 | 0.6599 | 0.6313 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
5,087 | 1,570,708 | $ 0.6664201 | $ 1,046,751 | - | 0.1986 - 5.64 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
19:27:13 | 25 | $ 0.6696 | USD |
Atara Biotherapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
67.27M | 101.92M | - | 63.57M | -230M | -2.26 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Atara Biotherapeutics News
Loading Messages....
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ATRA Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.6354 | 0.77 | 0.5719 | 0.667828 | 2,847,552 | 0.0342 | 5.38% |
1 Month | 1.35 | 1.35 | 0.1986 | 0.3941939 | 10,517,023 | -0.6804 | -50.4% |
3 Months | 1.58 | 1.96 | 0.1986 | 0.6088463 | 4,218,164 | -0.9104 | -57.62% |
6 Months | 1.59 | 2.535 | 0.1986 | 0.9934883 | 2,804,157 | -0.9204 | -57.89% |
1 Year | 4.65 | 5.64 | 0.1986 | 1.72 | 2,120,234 | -3.98 | -85.6% |
3 Years | 27.05 | 28.20 | 0.1986 | 6.13 | 1,493,033 | -26.38 | -97.52% |
5 Years | 39.82 | 43.9336 | 0.1986 | 8.83 | 1,194,138 | -39.15 | -98.32% |
Atara Biotherapeutics Description
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. The company's product candidates comprise Tab-cel, ATA188, and CAR T Programs. |